Thalidomide effects in the post-transplantation setting in patients with multiple myeloma

Edgardo S. Santos, Mark Goodman, John Byrnes, Hugo F. Fernandez

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Thalidomide recently has been proven to have an impact on plasma cell dyscrasia through multiple mechanisms. Its effects on hematopoietic stem cells both in harvesting and in the immediate post-transplant setting are still unknown. We report on 12 cases (9 males and 3 females), median age 56 years old (range 41-65 years old) who underwent autologous peripheral stem cell transplantation for multiple myeloma and received thalidomide as maintenance therapy post-transplantation. Patients received various cytoreductive therapies prior to stem cell harvest. Eleven patients were in partial remission (PR) and one in complete remission (CR) on entry into the transplant phase of therapy. The median CD34 +/kg harvested was 4.7 × 10 6 (range 1.9-55.4 × 10 6 CD34 +/kg). All patients received intravenous melphalan 200mg/m 2 as their conditioning regimen. Six of twelve patients attained a CR post-transplant, and six a PR. Thalidomide was started after all patients engrafted post-transplant (absolute neutrophil count >0.5 × 10 9/l and self-sustained platelet count >20 × 10 9/l) and following satisfactory resolution of transplant toxicity including mucositis and diarrhea. Thalidomide was initiated at a median of 43 days post-transplant (range 23-138 days). The median leukocyte and platelet counts at the moment of thalidomide initiation were 5.8 × 10 9/l (range 2.9-8.6 × 10 9/l) and 196 × 10 9/l (range 30-351 × 10 9/l), respectively. Thalidomide was started at 100 mg daily, increasing 100 mg/day/month until reaching a dose of 400 mg/day. One patient failed to tolerate thalidomide due to CNS symptoms and stopped therapy at 12 days. Another patient stopped thalidomide therapy after 71 days, because of severe fatigue secondary to hypothyroidism. The most common adverse effects were constipation (5), rash (4), dry skin (3) and dizziness (3). No grade 3-4 adverse effects were documented. Neutropenia, previously reported as an adverse effect in this setting, was not seen to date in our cohort. All patients attained a CR or PR after transplant and thalidomide maintenance. We have had two relapses during a median follow-up of 68 weeks (range 42-172 weeks). Conclusion: Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity. Longer follow up and future randomized trials will be needed to validate the role of thalidomide and its long-term effect when used as maintenance therapy in the post-transplant setting.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalHematology
Volume9
Issue number1
StatePublished - Feb 1 2004

Fingerprint

Thalidomide
Multiple Myeloma
Transplantation
Transplants
Platelet Count
Therapeutics
Peripheral Blood Stem Cell Transplantation
Mucositis
Paraproteinemias
Melphalan
Dizziness
Constipation
Hematopoietic Stem Cells
Hypothyroidism
Exanthema
Neutropenia
Leukocyte Count
Fatigue
Diarrhea
Neutrophils

Keywords

  • Multiple myeloma
  • Post-transplantation
  • Side effects
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. / Santos, Edgardo S.; Goodman, Mark; Byrnes, John; Fernandez, Hugo F.

In: Hematology, Vol. 9, No. 1, 01.02.2004, p. 35-39.

Research output: Contribution to journalArticle

@article{a9fac82a1dc742b195c3601e560060bb,
title = "Thalidomide effects in the post-transplantation setting in patients with multiple myeloma",
abstract = "Thalidomide recently has been proven to have an impact on plasma cell dyscrasia through multiple mechanisms. Its effects on hematopoietic stem cells both in harvesting and in the immediate post-transplant setting are still unknown. We report on 12 cases (9 males and 3 females), median age 56 years old (range 41-65 years old) who underwent autologous peripheral stem cell transplantation for multiple myeloma and received thalidomide as maintenance therapy post-transplantation. Patients received various cytoreductive therapies prior to stem cell harvest. Eleven patients were in partial remission (PR) and one in complete remission (CR) on entry into the transplant phase of therapy. The median CD34 +/kg harvested was 4.7 × 10 6 (range 1.9-55.4 × 10 6 CD34 +/kg). All patients received intravenous melphalan 200mg/m 2 as their conditioning regimen. Six of twelve patients attained a CR post-transplant, and six a PR. Thalidomide was started after all patients engrafted post-transplant (absolute neutrophil count >0.5 × 10 9/l and self-sustained platelet count >20 × 10 9/l) and following satisfactory resolution of transplant toxicity including mucositis and diarrhea. Thalidomide was initiated at a median of 43 days post-transplant (range 23-138 days). The median leukocyte and platelet counts at the moment of thalidomide initiation were 5.8 × 10 9/l (range 2.9-8.6 × 10 9/l) and 196 × 10 9/l (range 30-351 × 10 9/l), respectively. Thalidomide was started at 100 mg daily, increasing 100 mg/day/month until reaching a dose of 400 mg/day. One patient failed to tolerate thalidomide due to CNS symptoms and stopped therapy at 12 days. Another patient stopped thalidomide therapy after 71 days, because of severe fatigue secondary to hypothyroidism. The most common adverse effects were constipation (5), rash (4), dry skin (3) and dizziness (3). No grade 3-4 adverse effects were documented. Neutropenia, previously reported as an adverse effect in this setting, was not seen to date in our cohort. All patients attained a CR or PR after transplant and thalidomide maintenance. We have had two relapses during a median follow-up of 68 weeks (range 42-172 weeks). Conclusion: Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity. Longer follow up and future randomized trials will be needed to validate the role of thalidomide and its long-term effect when used as maintenance therapy in the post-transplant setting.",
keywords = "Multiple myeloma, Post-transplantation, Side effects, Thalidomide",
author = "Santos, {Edgardo S.} and Mark Goodman and John Byrnes and Fernandez, {Hugo F.}",
year = "2004",
month = "2",
day = "1",
language = "English",
volume = "9",
pages = "35--39",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Thalidomide effects in the post-transplantation setting in patients with multiple myeloma

AU - Santos, Edgardo S.

AU - Goodman, Mark

AU - Byrnes, John

AU - Fernandez, Hugo F.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Thalidomide recently has been proven to have an impact on plasma cell dyscrasia through multiple mechanisms. Its effects on hematopoietic stem cells both in harvesting and in the immediate post-transplant setting are still unknown. We report on 12 cases (9 males and 3 females), median age 56 years old (range 41-65 years old) who underwent autologous peripheral stem cell transplantation for multiple myeloma and received thalidomide as maintenance therapy post-transplantation. Patients received various cytoreductive therapies prior to stem cell harvest. Eleven patients were in partial remission (PR) and one in complete remission (CR) on entry into the transplant phase of therapy. The median CD34 +/kg harvested was 4.7 × 10 6 (range 1.9-55.4 × 10 6 CD34 +/kg). All patients received intravenous melphalan 200mg/m 2 as their conditioning regimen. Six of twelve patients attained a CR post-transplant, and six a PR. Thalidomide was started after all patients engrafted post-transplant (absolute neutrophil count >0.5 × 10 9/l and self-sustained platelet count >20 × 10 9/l) and following satisfactory resolution of transplant toxicity including mucositis and diarrhea. Thalidomide was initiated at a median of 43 days post-transplant (range 23-138 days). The median leukocyte and platelet counts at the moment of thalidomide initiation were 5.8 × 10 9/l (range 2.9-8.6 × 10 9/l) and 196 × 10 9/l (range 30-351 × 10 9/l), respectively. Thalidomide was started at 100 mg daily, increasing 100 mg/day/month until reaching a dose of 400 mg/day. One patient failed to tolerate thalidomide due to CNS symptoms and stopped therapy at 12 days. Another patient stopped thalidomide therapy after 71 days, because of severe fatigue secondary to hypothyroidism. The most common adverse effects were constipation (5), rash (4), dry skin (3) and dizziness (3). No grade 3-4 adverse effects were documented. Neutropenia, previously reported as an adverse effect in this setting, was not seen to date in our cohort. All patients attained a CR or PR after transplant and thalidomide maintenance. We have had two relapses during a median follow-up of 68 weeks (range 42-172 weeks). Conclusion: Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity. Longer follow up and future randomized trials will be needed to validate the role of thalidomide and its long-term effect when used as maintenance therapy in the post-transplant setting.

AB - Thalidomide recently has been proven to have an impact on plasma cell dyscrasia through multiple mechanisms. Its effects on hematopoietic stem cells both in harvesting and in the immediate post-transplant setting are still unknown. We report on 12 cases (9 males and 3 females), median age 56 years old (range 41-65 years old) who underwent autologous peripheral stem cell transplantation for multiple myeloma and received thalidomide as maintenance therapy post-transplantation. Patients received various cytoreductive therapies prior to stem cell harvest. Eleven patients were in partial remission (PR) and one in complete remission (CR) on entry into the transplant phase of therapy. The median CD34 +/kg harvested was 4.7 × 10 6 (range 1.9-55.4 × 10 6 CD34 +/kg). All patients received intravenous melphalan 200mg/m 2 as their conditioning regimen. Six of twelve patients attained a CR post-transplant, and six a PR. Thalidomide was started after all patients engrafted post-transplant (absolute neutrophil count >0.5 × 10 9/l and self-sustained platelet count >20 × 10 9/l) and following satisfactory resolution of transplant toxicity including mucositis and diarrhea. Thalidomide was initiated at a median of 43 days post-transplant (range 23-138 days). The median leukocyte and platelet counts at the moment of thalidomide initiation were 5.8 × 10 9/l (range 2.9-8.6 × 10 9/l) and 196 × 10 9/l (range 30-351 × 10 9/l), respectively. Thalidomide was started at 100 mg daily, increasing 100 mg/day/month until reaching a dose of 400 mg/day. One patient failed to tolerate thalidomide due to CNS symptoms and stopped therapy at 12 days. Another patient stopped thalidomide therapy after 71 days, because of severe fatigue secondary to hypothyroidism. The most common adverse effects were constipation (5), rash (4), dry skin (3) and dizziness (3). No grade 3-4 adverse effects were documented. Neutropenia, previously reported as an adverse effect in this setting, was not seen to date in our cohort. All patients attained a CR or PR after transplant and thalidomide maintenance. We have had two relapses during a median follow-up of 68 weeks (range 42-172 weeks). Conclusion: Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity. Longer follow up and future randomized trials will be needed to validate the role of thalidomide and its long-term effect when used as maintenance therapy in the post-transplant setting.

KW - Multiple myeloma

KW - Post-transplantation

KW - Side effects

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=1342288315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342288315&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 35

EP - 39

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 1

ER -